Skip to main content
Premium Trial:

Request an Annual Quote

Admera Health Lands New Jersey Approval for OncoGxSelect

NEW YORK (GenomeWeb) – Rosetta Genomics today announced that its sales partner Admera Health has received approval from the New Jersey Department of Health (NJDH) for the OncoGxSelect panel for clinical use.

Admera's next-generation sequencing-based oncology panel looks at five genes associated with lung cancer. The test detects point mutations, small indels, and gene fusions in KRAS, BRAF, EGFR, ROS1, and ALK to provide clinically actionable results. OncoGxSelect is performed on formalin-fixed, paraffin-embedded tissue samples.

OncoGxSelect will be available through Rosetta Genomics. In October 2014, Rosetta Genomics signed a sales and marketing agreement to sell Admera's tests. Pricing for the newly approved test was not disclosed.

"Feedback from physicians has highlighted the importance of offering a panel that is limited to those mutations that are truly actionable," Rosetta Genomics CEO Kenneth Berlin said in a statement. "This is particularly helpful as it reduces the 'noise and distraction' of variations of unknown significance."

In May, Admera received NJDH approval for its PGxOne Plus and OncoGxOne tests.